Portal de Periódicos da CAPES

Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model

2006; Lippincott Williams & Wilkins; Volume: 175; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(05)00893-1

1527-3792

Yair Lotan, Jennifer Stanfield, L. Chinsoo Cho, Jennifer B. Sherwood, Khaled Abdel‐Aziz, Cheng-Hui Chang, Kenneth Forster, Wareef Kabbani, Jer‐Tsong Hsieh, Hak Choy, Robert Timmerman,

Molecular Biology Techniques and Applications

No AccessJournal of UrologyInvestigative urology1 May 2006Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model Yair Lotan, Jennifer Stanfield, L. Chinsoo Cho, Jennifer B. Sherwood, Khaled F. Abdel-Aziz, Cheng-Hui Chang, Kenneth Forster, Wareef Kabbani, Jer-Tsong Hsieh, Hak Choy, and Robert Timmerman Yair LotanYair Lotan Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas , Jennifer StanfieldJennifer Stanfield Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas , L. Chinsoo ChoL. Chinsoo Cho Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas , Jennifer B. SherwoodJennifer B. Sherwood Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas , Khaled F. Abdel-AzizKhaled F. Abdel-Aziz Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas , Cheng-Hui ChangCheng-Hui Chang Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas , Kenneth ForsterKenneth Forster Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas , Wareef KabbaniWareef Kabbani Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas , Jer-Tsong HsiehJer-Tsong Hsieh Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas , Hak ChoyHak Choy Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas , and Robert TimmermanRobert Timmerman Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00893-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: SBRT is a new therapeutic paradigm using large dose per fraction treatments (aggressive hypofractionation). While SBRT has shown efficacy for treating patients with lung, liver and spine tumors, to our knowledge there have been no preclinical studies evaluating the efficacy of this treatment for prostate cancer. We investigated the dose-response characteristics of SBRT for treating human prostate cancer in a nude mouse model. Materials and Methods: Nude mice were injected subcutaneously into the right flank with C4-2 prostate cancer cells grown in culture. A dose escalation trial was performed to assess toxicity and response. Tumor bearing animals were radiated with 3 fractions (1 per week) for a total dose of 15 Gy in 11, 22.5 Gy in 9 and 45 Gy in 10, while 8 untreated animals served as controls. The mice were weighed, and tumor volume and PSA measurements were performed at baseline and weekly until 4 weeks after treatment. Results: There was no treatment related toxicity. There was a significant difference in the tumor response to higher radiation doses. In the 15 and 22.5 Gy groups mean tumor volume decreased to 58% and 90% of the original volume, respectively, but the rats experienced progressive tumor regrowth within 1 week after the completion of therapy. The 45 Gy group had a mean tumor volume and PSA decrease of greater than 90%, which was sustained 1 month after treatment in all except 2 mice. Conclusions: SBRT dose level treatments were able to significantly decrease tumor volume and PSA. However, using 15 and 22.5 Gy durable responses were not achieved except in a few mice. The 45 Gy group demonstrated sustained PSA and tumor volume decreases in most mice. These results clearly show an increasing dose-response relationship for a range of hypofractionated dose levels, as used in SBRT. References 1 : Cancer statistics, 2004. CA Cancer J Clin2004; 54: 8. Google Scholar 2 : Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. J Urol1995; 154: 2144. Link, Google Scholar 3 : Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys1999; 43: 1095. Google Scholar 4 : A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys2001; 51: 213. Google Scholar 5 : Is the alpha/beta ratio for prostate cancer low?. Int J Radiat Oncol Biol Phys2001; 51:: 1. Google Scholar 6 : 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer: A pilot study. Strahlenther Onkol2004; 180: 225. Google Scholar 7 : Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys2002; 53: 316. Google Scholar 8 : Predictors of survival after a positive post-irradiation prostate biopsy. Int J Radiat Oncol Biol Phys1994; 28: 17. Google Scholar 9 : Should brachytherapy be considered a therapeutic option in localized prostate cancer?. Urol Clin North Am1996; 23:: 633. Google Scholar 10 : The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol1986; 135: 510. Link, Google Scholar 11 : The CyberKnife stereotactic radiosurgery system: description, installation, and an initial evaluation of use and functionality. Neurosurgery2003; 53: 1235. Google Scholar 12 : Extracranial stereotactic radiation delivery: expansion of technology beyond the brain. Technol Cancer Res Treat2003; 2: 153. Google Scholar 13 : Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest2003; 124: 1946. Google Scholar 14 : Dose, time and fractionation a clinical hypothesis. Clin Radiol1969; 20: 1. Google Scholar 15 : Stereotactic Body Radiation Therapy. Baltimore: Lippincott, Williams and Wilkins2005. pp. 140–142. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byTaneja S (2019) Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 TrialJournal of Urology, VOL. 203, NO. 1, (32-32), Online publication date: 1-Jan-2020.Taneja S (2019) Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate CancerJournal of Urology, VOL. 201, NO. 5, (859-859), Online publication date: 1-May-2019.Taneja S (2018) Re: Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized TrialJournal of Urology, VOL. 199, NO. 3, (609-610), Online publication date: 1-Mar-2018.Taneja S (2018) Re: Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II StudyJournal of Urology, VOL. 200, NO. 1, (28-30), Online publication date: 1-Jul-2018.Taneja S (2018) Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP TrialJournal of Urology, VOL. 196, NO. 5, (1445-1447), Online publication date: 1-Nov-2016.Taneja S (2018) Re: Use, Complications, and Costs of Stereotactic Body Radiotherapy for Localized Prostate CancerJournal of Urology, VOL. 196, NO. 6, (1676-1677), Online publication date: 1-Dec-2016.Taneja S (2018) Re: Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate CancerJournal of Urology, VOL. 191, NO. 4, (983-985), Online publication date: 1-Apr-2014. Volume 175Issue 5May 2006Page: 1932-1936 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsnudemiceprostatic neoplasmsradiotherapyprostateparticle acceleratorsMetricsAuthor Information Yair Lotan Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Jennifer Stanfield Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author L. Chinsoo Cho Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Jennifer B. Sherwood Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Khaled F. Abdel-Aziz Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Cheng-Hui Chang Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Kenneth Forster Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Wareef Kabbani Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Jer-Tsong Hsieh Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Hak Choy Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Robert Timmerman Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas More articles by this author Expand All Advertisement PDF downloadLoading ...